Results 111 to 120 of about 1,627 (175)

Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma. [PDF]

Nucl Med Mol Imaging
Kim D, Lee SH, Hwang HS, Kim SJ, Yun M.
europepmc   +1 more source

[¹⁸F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response. [PDF]

Nucl Med Biol
McNeal KC, Reeves KM, Song PN, Lapi SE, Sorace AG, Larimer BM.   +5 more
europepmc   +1 more source

An Organoid Model for the Therapeutic Effect of Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. [PDF]

Ann Surg Oncol
Liu D, Chen Z, Deng W, Lan J, Zhu Y, Wang H, Xu X, Zhang Y, Wu X, Yang K, Cai J.   +10 more
europepmc   +1 more source

Misonidazole neuropathy A prospective study

Journal of Neuro-Oncology, 1988
The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the ...
Jens Overgaard, Olaf B Paulson, Overgaard J   +2 more
exaly   +7 more sources

Misonidazole neuropathy.

Acta neurologica Scandinavica. Supplementum, 1984
Neurotoxic side effects of misonidazole with peripheral neuropathy was investigated in two series of patients. The first series consisted of eight patients with carcinoma of the pharynx, larynx or lung who, during treatment with misonidazole, developed peripheral neuropathy dominated by severe sensory symptoms and signs localized mainly to the lower ...
Paulson, O B, Melgaard, B, Hansen, H S, Kamieniecka, Z, Køhler, O, Hansen, J M, Pedersen, A G, Tang, X, Trojaborg, W   +8 more
openaire   +2 more sources

Kinetics of misonidazole enantiomers

Clinical Pharmacology and Therapeutics, 1984
The kinetics of misonidazole enantiomers were followed in nine healthy subjects after a single oral dose of racemic misonidazole (1.0 gm/m2). Mean clearance of (+)-misonidazole was 14% greater than that for (-)-misonidazole and mean volume of distribution was slightly greater (3%) for the (+)-enantiomer.
K M Williams
openaire   +3 more sources

Ascorbate-enhanced Cytotoxicity of misonidazole

Nature, 1978
MISONIDAZOLE, an electron-affinic, nitroheterocyclic compound (1-(2-nitro-1-imidazole)-3 methoxy-2-propanol, Ro-07-0582) is undergoing preliminary clinical trials, which are exploring its capacity to sensitise hypoxic tumour cells to ionising radiation damage1–4. The drug also possesses a substantial cytotoxic effect, independent of radiation, which is
P D, Josephy, B, Palcic, L D, Skarsgard
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Enhancement of artificial lung metastases by misonidazole

International Journal of Radiation Oncology Biology Physics, 1984
The effect of treatment with the hypoxic cell radiosensitizer misonidazole on the formation of artificial lung metastases was examined. Both single treatments with large doses of misonidazole and fractionated treatments with smaller doses of misonidazole were found to increase the number of lung tumors developing after intravenous injection of EMT6 ...
Sara Rockwell, S Rockwell
exaly   +3 more sources

Misonidazole and potentially lethal damage

International Journal of Radiation Oncology*Biology*Physics, 1982
The existence of potentially lethal damage (PLD) is demonstrated in exponentially growing CHO cells exposed to misonidazole in hypoxia. The method of hypertonic post-treatment of cells was used in these studies. Misonidazole-induced PLD differs in many characteristics from radiation-induced PLD.
M, Korbelik, B, Palcic, K, Skov, L, Skarsgard   +3 more
openaire   +3 more sources